From psychedelic-assisted therapy to embryo models and cellular therapies at the nanoscale, science is rapidly expanding the boundaries of what is possible in healthcare. Australia has often been at the forefront of these developments.
Yet while the science moves forward, the laws and regulations designed to protect patients and ensure safe access remain increasingly out of step with emerging technologies.
Dr Christopher Rudge, Deputy Director of Sydney Health Law, is examining how well Australia's current frameworks are equipped to handle the medical technologies of tomorrow.
His research reveals a system marked by rigidity, inconsistency and gaps that can stifle innovation while raising patient safety concerns.
Critical pressure points
His work identifies critical pressure points across the medical frontier. For psychedelic-assisted therapy, he and his colleague Reeve McClelland (pictured, above) have revealed how inconsistent state laws create unequal access while exposing patients to risks from unlawful advertising and exploitation.
For personalised nanomedicines, Dr Rudge critiques a narrow regulatory focus on risk-based clinical trials. He argues that regulation needs to become more adaptive, especially where clinical evidence cannot be generated in cases of rare diseases or bespoke treatments.
Current models of regulatory approval can create blind spots by shifting responsibility from the regulator to the patient, leaving space where foreseeable harm can occur.
"Our current regulatory system was designed for a different era of medicine," Dr Rudge said.
We are squeezing breakthrough therapies into rigid boxes, creating missed opportunities for patients and untold frustration for researchers.
Dr Christopher Rudge
From patchwork to blueprint
These challenges amount to what Dr Rudge calls a 'regulatory patchwork'—a fragmented system that struggles to keep pace with scientific progress. In response, his research proposes a blueprint for reform: a more adaptive, consistent and collaborative national framework that can evolve alongside science.
Central to this vision is the introduction of 'regulatory sandboxes', controlled legal environments where innovators and regulators can collaborate to test new therapies and co-design adaptable rules.
"A sandbox allows regulators to learn alongside innovators, rather than scrambling to catch up once therapies are already in use," Dr Rudge explained.
"It's about creating clearer pathways from the lab to the clinic.”
Ready for the future
By identifying pressure points and crafting practical reforms, Dr Rudge seeks to develop the foundations of a legal system capable of supporting innovation while safeguarding patients.
"New medicines will continue to emerge in ways we can't yet predict," he said.
"If Australia wants to remain a leader in health innovation, we need laws that are not just reactive, but prepared for what's coming."
His work underscores the challenge: as science continues to advance, the law must adapt — not as a barrier to innovation but as an ally in fostering safe, equitable and accessible health care.
Manual Name : Dr Christopher Rudge
Manual Description : Sydney Law School
Manual Address :
Manual Addition Info Title :
Manual Addition Info Content :
Profile image : /content/dam/corporate/images/sydney-law-school/people/christopher-rudge.jpg
Manual Type : profile
_self
Auto Type : contact
Auto Addition Title :
Auto Addition Content :
Auto Name : true
Auto Position : true
Auto Profile image :
Auto Phone Number : false
Auto Mobile Number : true
Auto Email Address : true
Auto Address : false
UUID :